Iranian
Biomedical Journal
Volume 23, Issue 4 (7-2019)
IBJ 2019, 23(4): 235-245 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hekmat S, Sadat S M, Aslani M M, Mahdavi M, Bolhassani A, Asgar Halvaee F, et al . Truncated Core/NS3 Fusion Protein of HCV Adjuvanted with Outer Membrane Vesicles of Neisseria meningitidis Serogroup B: Potent Inducer of the Murine Immune System. IBJ 2019; 23 (4) :235-245
URL: http://ibj.pasteur.ac.ir/article-1-2576-en.html
URL: http://ibj.pasteur.ac.ir/article-1-2576-en.html
Soheila Hekmat 
, Seyed Mehdi Sadat , Mohammad Mehdi Aslani , Mehdi Mahdavi , Azam Bolhassani , Fateme Asgar Halvaee , Seyed Mohammad Mahdi Ghahari , Mohammad Reza Aghasadeghi , Seyed Davar Siadat
, Seyed Mehdi Sadat , Mohammad Mehdi Aslani , Mehdi Mahdavi , Azam Bolhassani , Fateme Asgar Halvaee , Seyed Mohammad Mahdi Ghahari , Mohammad Reza Aghasadeghi , Seyed Davar Siadat
Abstract:
Background: A licensed vaccine against hepatitis C virus (HCV) has not become available to date. The stability and antigenicity of a targeted synthesized recombinant fusion protein consisting of a truncated core and NS3 (rC/N) of HCV had been predicted. Although safe antigens, recombinant proteins are not efficacious vaccines without adjuvants. The present study evaluated the immunogenicity of rC/N as a bipartite antigen accompanied by Neisseria meningitidis serogroup B outer membrane vesicles (NMB OMVs) in BALB/c mice. Methods: The NMB OMVs were produced and evaluated accurately. The administrations were as follows: rC/N-OMV, rC/N-Freund’s complete/incomplete adjuvant (CIA), rC/N-MF59, rC/N, OMV, MF59, and PBS. The production of Th1 (IFN-γ, IL-2)/Th2 (IL-4)/Th17 (IL-17) cytokines and granzyme B (cytotoxic indicator) by splenic mononuclear cells and the humoral concentration of total IgG/IgG1 (Th2)/IgG2a (Th1) in sera of mice were measured using mouse ELISA kits. Results: Concentrations of Th1/Th2/Th17 cytokines, granzyme B, and immunoglobulins in the spleens and sera of immunized mice, which had received antigen plus each adjuvant (rC/N-OMV, rC/N-Freund’s CIA and rC/N-MF59), significantly raised compared to the controls (rC/N, OMV, MF59 and PBS). Th1-type responses were dominant over Th2-type responses in vaccinated mice with rC/N-OMV, and Th2 type responses increased dominantly in vaccinated mice with rC/N-MF59 (p < 0.05). Conclusion: NMB OMVs were able to increase Th1 immune responses dramatically more than MF59 and Freund’s CIA. The formulation of rC/N with NMB OMVs showed its ability to induce Th1, Th2, and Th17 immune responses. rC/N-NMB OMVs is a promising approach for the development of an HCV therapeutic vaccine.
Type of Study: Full Length/Original Article |
Subject:
Molecular Immunology & Vaccines
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |